Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Stock Analysis & Ratings

ARQT Stock Chart & Stats

Day’s Range$17.37 - $18.68
52-Week Range$13.59 - $29.37
Previous Close$17.93
Average Volume (3M)262.77K
Market Cap$938.38M
P/E Ratio-3.9
Next EarningsAug 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)-4.67



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $13.59 and its highest was $29.37 in the past 12 months.
    What is Arcutis Biotherapeutics’s market cap?
    Arcutis Biotherapeutics’s market cap is $938.38M.
      What is Arcutis Biotherapeutics’s price target?
      The average price target for Arcutis Biotherapeutics is $47.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $57.00 ,the lowest forecast is $36.00. The average price target represents 157.53% Increase from the current price of $18.25.
        What do analysts say about Arcutis Biotherapeutics?
        Arcutis Biotherapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Arcutis Biotherapeutics’s upcoming earnings report date?
          Arcutis Biotherapeutics’s upcoming earnings report date is Aug 16, 2022 which is in 90 days.
            How were Arcutis Biotherapeutics’s earnings last quarter?
            Arcutis Biotherapeutics released its earnings results on May 05, 2022. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.502 by $0.232.
              Is Arcutis Biotherapeutics overvalued?
              According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
                Does Arcutis Biotherapeutics pay dividends?
                Arcutis Biotherapeutics does not currently pay dividends.
                What is Arcutis Biotherapeutics’s EPS estimate?
                Arcutis Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Arcutis Biotherapeutics have?
                Arcutis Biotherapeutics has 51,420,000 shares outstanding.
                  What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
                  Arcutis Biotherapeutics reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.502. Following the earnings report the stock price went down -7.707%.
                    Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
                    Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Omega Fund Management, LLC. It holds Arcutis Biotherapeutics’s shares valued at 12M.


                      Arcutis Biotherapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(157.53% Upside)
                      Strong Buy
                      The Arcutis Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Arcutis Biotherapeutics

                      Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.

                      Similar Stocks
                      Price & Change
                      Black Diamond Therapeutics
                      Passage Bio
                      Revolution Medicines
                      Aprea Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis